Department of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, 3181 South West Sam Jackson Park Road, Suite 140, Portland, OR 97239, USA.
Pituitary. 2012 Sep;15(3):301-10. doi: 10.1007/s11102-011-0372-6.
Growth hormone (GH) is approved by the US Food and Drug Administration (FDA) for use in pediatric patients with disorders of growth failure or short stature and in adults with growth hormone deficiency (GHD) and HIV/AIDS wasting and cachexia. For pediatric patients, guidelines for the use of GH have been developed by several organizations that have identified specific criteria for initiating GH therapy for each FDA-approved indication. Guidelines for adults have also been developed and include recommendations for transition (adolescent) patients with GHD. These patients are often treated with GH as children but may require continued treatment as young adults to attain full skeletal mineralization and improve cardiovascular risk factors. Adult and pediatric guidelines are supported by efficacy and safety studies, which show that, when started at an early age, GH treatment can increase growth velocity and that GH is safe and well-tolerated. We summarize the guidelines that are available for all FDA-approved indications among pediatric and transition patients. Adherence to these guidelines will help to ensure that patients with disorders of growth failure or short stature receive the necessary therapy to increase linear growth and transition smoothly to healthy adulthood.
生长激素（GH）已获得美国食品和药物管理局（FDA）批准，可用于治疗生长障碍或身材矮小的儿科患者以及生长激素缺乏症（GHD）和 HIV/AIDS 消瘦和恶病质的成年患者。对于儿科患者，多个组织制定了 GH 使用指南，为每种 FDA 批准的适应症确定了启动 GH 治疗的具体标准。还制定了成人指南，包括对 GHD 青少年过渡患者的建议。这些患者通常在儿童时期接受 GH 治疗，但可能需要在年轻成人时期继续治疗，以实现完全骨骼矿化并改善心血管危险因素。成人和儿科指南得到了疗效和安全性研究的支持，这些研究表明，在早期开始治疗时，GH 治疗可以增加生长速度，并且 GH 是安全且耐受良好的。我们总结了儿科和过渡患者所有 FDA 批准适应症的指南。遵守这些指南将有助于确保生长障碍或身材矮小的患者接受必要的治疗以增加线性生长，并顺利过渡到健康的成年期。
